Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Christian Gisselbrecht

Biology of Blood and Marrow Transplantation, In Press, Uncorrected Proof, Available online 1 September 2014

Before the era of rituximab, high-dose chemotherapy with autologous stem cell transplantation (ASCT) served as the standard of care for relapsed, aggressive diffuse large B cell lumphoma (DLBCL) that was chemosensitive to salvage chemotherapy. Dramatic improvement has been observed with the addition of rituximab to chemotherapy. Nevertheless, depending on clinical and biological prognostic factors, some patients  will not be cured because they are refractory to first-line treatment or because they have relapsed. Could a different behavior be expected in relapsed disease because of the introduction of rituximab, thus questioning the place of auto-transplantation? The COllaborative trial in Relapsed Aggressive Lymphoma (CORAL) study was designed as an international effort to determine which salvage regimens should be proposed to patients with relapsed DLBCL and to evaluate the place of rituximab for maintenance after ASCT, but some of the conclusions were disappointing.


E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


Search this site

Search form